AMGN compared with LXEO: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

LXEOLexeo Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

LXEOLexeo Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

LXEO: latest quarter not drawable.Method ›

Price

rebased to 0%

AMGN, solidLXEO, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No disclosed counterparties: LXEO.

Only LXEO 0

None

Role chip = supplier or customerSource: SEC EDGAR

AMGNAmgen Inc

478.34· pre 479.81· delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

LXEOLexeo Therapeutics, Inc.

3.12· pre 3.27· delayed

Pre-marketNov 5 '26delayed

Mkt cap$265.0MRevenue—Revenue—

Compare

Pre-marketNov 5 '26delayed

AMGNAmgen Inc

LXEOLexeo Therapeutics, Inc.

478.34pre 479.81delayed

Price

3.12pre 3.27delayed

$258.8B

Mkt cap

$265.0M

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN478.34vsLXEO3.12Pre-marketNov 5 '26delayed